Literature DB >> 7684430

The 26-kD transmembrane form of tumor necrosis factor alpha on activated CD4+ T cell clones provides a costimulatory signal for human B cell activation.

G Aversa1, J Punnonen, J E de Vries.   

Abstract

Interleukin 4 (IL-4) induces immunoglobulin (Ig)E and IgG4 synthesis in human B cells. In addition to IL-4, costimulatory signals provided by activated CD4+ T cells are required for productive IgG4 and IgE synthesis. Here we report that the 26-kD transmembrane form of tumor necrosis factor alpha (mTNF-alpha), which is rapidly expressed on CD4+ T cell clones after activation, contributes to the costimulatory signals resulting in IL-4-dependent Ig synthesis by B cells, including IgG4 and IgE production. mTNF-alpha expression was induced on T cell clones within 2 h after activation with concanavalin A. Peak expression was observed at 24 h, followed by a gradual decrease, but appreciable levels of mTNF-alpha were still detectable 72 h after activation. The presence of the 26-kD membrane form of TNF-alpha on activated T cell clones was confirmed by immunoprecipitation. Monoclonal antibodies (mAbs) recognizing mTNF-alpha, or the p55 TNF receptor, inhibited IgM, IgG, IgG4, and IgE synthesis induced by IL-4 and activated CD4+ T cell clones in cultures of highly purified surface IgD+ B cells. The anti-TNF-alpha mAbs also blocked Ig production in cultures in which the activated CD4+ T cell clones were replaced by their plasma membranes. Furthermore, pretreatment of the plasma membranes with anti-TNF-alpha mAbs strongly reduced their capacity to stimulate B cells to produce Ig in the presence of IL-4, indicating that the anti-TNF-alpha mAbs blocked the effects of mTNF-alpha. Anti-TNF-alpha mAbs did not affect IgM, IgG, IgG4, or IgE synthesis induced by anti-CD40 mAbs and IL-4 in the absence of CD4+ T cells, supporting the notion that the anti-TNF-alpha mAbs indeed interfered with the costimulatory, contact-mediated signal provided by T cells, or their membranes. Collectively these results indicate that mTNF-alpha, which is rapidly induced after activation of CD4+ T cells, participates in productive T-B cell interactions resulting in IL-4-induced Ig production. This is a novel property of the T cell membrane form of TNF-alpha.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7684430      PMCID: PMC2191054          DOI: 10.1084/jem.177.6.1575

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  39 in total

1.  Separation of events mediating B cell proliferation and Ig production by using T cell membranes and lymphokines.

Authors:  P D Hodgkin; L C Yamashita; R L Coffman; M R Kehry
Journal:  J Immunol       Date:  1990-10-01       Impact factor: 5.422

2.  A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact.

Authors:  C Perez; I Albert; K DeFay; N Zachariades; L Gooding; M Kriegler
Journal:  Cell       Date:  1990-10-19       Impact factor: 41.582

3.  Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies.

Authors:  M Brockhaus; H J Schoenfeld; E J Schlaeger; W Hunziker; W Lesslauer; H Loetscher
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

4.  Noncognate contact-dependent B cell activation can promote IL-4-dependent in vitro human IgE synthesis.

Authors:  P Parronchi; A Tiri; D Macchia; M De Carli; P Biswas; C Simonelli; E Maggi; G Del Prete; M Ricci; S Romagnani
Journal:  J Immunol       Date:  1990-03-15       Impact factor: 5.422

5.  A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins.

Authors:  C A Smith; T Davis; D Anderson; L Solam; M P Beckmann; R Jerzy; S K Dower; D Cosman; R G Goodwin
Journal:  Science       Date:  1990-05-25       Impact factor: 47.728

6.  Evidence for the existence of two forms of membrane tumor necrosis factor: an integral protein and a molecule attached to its receptor.

Authors:  B Luettig; T Decker; M L Lohmann-Matthes
Journal:  J Immunol       Date:  1989-12-15       Impact factor: 5.422

7.  Structure and expression of germline epsilon transcripts in human B cells induced by interleukin 4 to switch to IgE production.

Authors:  J F Gauchat; D A Lebman; R L Coffman; H Gascan; J E de Vries
Journal:  J Exp Med       Date:  1990-08-01       Impact factor: 14.307

8.  Induction of human IgE synthesis by CD4+ T cell clones. Requirement for interleukin 4 and low molecular weight B cell growth factor.

Authors:  R H DeKruyff; T Turner; J S Abrams; M A Palladino; D T Umetsu
Journal:  J Exp Med       Date:  1989-11-01       Impact factor: 14.307

9.  A novel addition to the T cell repertory. Cell surface expression of tumor necrosis factor/cachectin by activated normal human T cells.

Authors:  M Kinkhabwala; P Sehajpal; E Skolnik; D Smith; V K Sharma; H Vlassara; A Cerami; M Suthanthiran
Journal:  J Exp Med       Date:  1990-03-01       Impact factor: 14.307

10.  Clonotypic structures involved in antigen-specific human T cell function. Relationship to the T3 molecular complex.

Authors:  S C Meuer; K A Fitzgerald; R E Hussey; J C Hodgdon; S F Schlossman; E L Reinherz
Journal:  J Exp Med       Date:  1983-02-01       Impact factor: 14.307

View more
  31 in total

1.  Regression of inflammatory myofibroblastic tumor of the gastrointestinal tract under infliximab treatment.

Authors:  Georgios Germanidis; Ioannis Xanthakis; Ioannis Tsitouridis; Thomas Zaramboukas; Dimitrios Kiskinis; Christos Konstantaras; Spiros Miliaras; Theodoros Sirakos; Emmanouil Pagkalos
Journal:  Dig Dis Sci       Date:  2005-02       Impact factor: 3.199

Review 2.  The CD40 ligand. At the center of the immune universe?

Authors:  I S Grewal; R A Flavell
Journal:  Immunol Res       Date:  1997-02       Impact factor: 2.829

3.  Transmembrane tumor necrosis factor alpha is required for enteropathy and is sufficient to promote parasite expulsion in gastrointestinal helminth infection.

Authors:  M X Ierna; H E Scales; C Mueller; C E Lawrence
Journal:  Infect Immun       Date:  2009-06-29       Impact factor: 3.441

4.  Antigen-presenting cell-derived signals determine expression levels of CD70 on primed T cells.

Authors:  S M Lens; P A Baars; B Hooibrink; M H van Oers; R A van Lier
Journal:  Immunology       Date:  1997-01       Impact factor: 7.397

5.  Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease.

Authors:  A Di Sabatino; R Ciccocioppo; B Cinque; D Millimaggi; R Morera; L Ricevuti; M G Cifone; G R Corazza
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

6.  T cell clones from an X-linked hyper-immunoglobulin (IgM) patient induce IgE synthesis in vitro despite expression of nonfunctional CD40 ligand.

Authors:  P Life; J F Gauchat; V Schnuriger; S Estoppey; G Mazzei; A Durandy; A Fischer; J Y Bonnefoy
Journal:  J Exp Med       Date:  1994-11-01       Impact factor: 14.307

7.  Unimpaired autoreactive T-cell traffic within the central nervous system during tumor necrosis factor receptor-mediated inhibition of experimental autoimmune encephalomyelitis.

Authors:  H Körner; A L Goodsall; F A Lemckert; B J Scallon; J Ghrayeb; A L Ford; J D Sedgwick
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

8.  BAFF selectively enhances the survival of plasmablasts generated from human memory B cells.

Authors:  Danielle T Avery; Susan L Kalled; Julia I Ellyard; Christine Ambrose; Sarah A Bixler; Marilyn Thien; Robert Brink; Fabienne Mackay; Philip D Hodgkin; Stuart G Tangye
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

Review 9.  Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents.

Authors:  Takahiko Horiuchi; Hiroki Mitoma; Shin-ichi Harashima; Hiroshi Tsukamoto; Terufumi Shimoda
Journal:  Rheumatology (Oxford)       Date:  2010-03-01       Impact factor: 7.580

10.  Tumor Therapy Applying Membrane-bound Form of Cytokines.

Authors:  Young Sang Kim
Journal:  Immune Netw       Date:  2009-10-30       Impact factor: 6.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.